" class="no-js "lang="en-US"> Tom Lemberg - Medtech Alert
Thursday, April 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Tom Lemberg

Tom Lemberg

About Tom Lemberg

Founder of Curebase, decentralized clinical trials. Helping any patient, anywhere participate in clinical trials at home and with their own doctor.

Related Story

Clinical Trials

 Curebase Secures $40 Million in Series B Funding | Pharmtech Focus

Curebase Secures $40 Million in Series B Funding

May 5 2022

Curebase, a company committed to democratizing access to clinical studies, has raised $40 million in […]

Clinical Trials

 Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health | Pharmtech Focus

Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health

March 14 2022

Curebase, a company committed to democratizing access to clinical studies, and Blue Note Therapeutics, a prescription […]